RecruitingNot ApplicableNCT05573074

Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33


Sponsor

NYU Langone Health

Enrollment

120 participants

Start Date

Apr 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing transcranial near-infrared radiation (tNIR) — a non-invasive light-based therapy applied to the head — to see if it improves blood flow in the brain and reduces depression symptoms. Researchers believe this approach may help regulate mood in people with major depressive disorder. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with major depressive disorder (MDD) and currently have significant depression symptoms - Your score on a standard depression scale is 23 or higher - You are willing to use contraception if you are a woman of childbearing age **You may NOT be eligible if...** - You have an active serious medical or psychiatric condition that would interfere with the study - You have a condition that makes it unsafe to receive the light-based treatment - Your depression is not the primary condition being treated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscranial Photobiomodulator

Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.

DEVICESham

Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2


Locations(3)

Harvard Medical School

Boston, Massachusetts, United States

NYU Langone Health

New York, New York, United States

Nathan Kline Institute for Psychiatric Research

Orangeburg, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05573074


Related Trials